Therefore, we can conclude that the Nintedanib antiangiogenic therapy is a promising strategy for both prevention and intervention of PCa, since it is capable of decreasing neovascularization, AR immunoreactivity and delaying tumor progression. This evidence concerns the gene AR and neoplasm.